Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

6.69USD
25 Sep 2017
Change (% chg)

-- (--)
Prev Close
$6.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
741,291
52-wk High
$8.84
52-wk Low
$1.51

Latest Key Developments (Source: Significant Developments)

Immunogen announces update to financial results year ended June 30, 2016 - SEC filing
Thursday, 25 Aug 2016 03:47pm EDT 

Immunogen Inc: Announces update to financial results for the quarter and year ended June 30, 2016 - SEC filing . Due to info that became available related to potential liability to a contract manufacturer, additional expense accrual was required . Due to the additional expense accrual, financial results have been adjusted .FY net loss increased to $144.8 million or $1.67 per share, will be reported as such in 10-K filing.  Full Article

Immunogen Q4 loss per share $0.51
Thursday, 4 Aug 2016 06:30am EDT 

Immunogen Inc : Q4 loss per share $0.51 . Immunogen reports fourth quarter and fiscal year 2016 financial results and provides quarterly business update . Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Phase 3 forward I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end. . Ended fiscal year with approximately $245 million in cash . For six months ending December 31, 2016, Immunogen expects revenues to be between $40 million and $45 million .For six months ending December 31, 2016, Immunogen expects net loss to be between $55 million and $60 million.  Full Article

ImmunoGen announces pricing of $100 mln offering of Senior Notes
Wednesday, 15 Jun 2016 08:58am EDT 

Immunogen Inc : Sale of notes is expected to result in $96.7 million net proceeds to Immunogen . Interest will be payable semi-annually in arrears on january 1 and july 1 of each year, beginning january 1, 2017 . Sale of notes expected to result in proceeds of $111.2 million if initial purchasers exercise option to purchase additional notes in full . Notes will be senior unsecured obligations of Immunogen, and will bear interest at a rate of 4.50% per year .Immunogen announces pricing of $100 million offering of 4.50% convertible senior notes due 2021.  Full Article

Immunogen announces proposed $100 mln offering of convertible senior notes
Monday, 13 Jun 2016 04:01pm EDT 

Immunogen Inc : Immunogen announces proposed $100 million offering of convertible senior notes due 2021 . Says notes will be senior unsecured obligations of immunogen, and interest will be payable semi-annually .Immunogen Inc says intends to use net proceeds of offering for its operations, including but not limited to clinical trial expenditures.  Full Article

ImmunoGen reports positive early-stage data on ovarian cancer drug
Wednesday, 18 May 2016 05:01pm EDT 

Immunogen : Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in frα-positive ovarian cancer . Company preparing to meet with FDA in early 3q 2016; targeting initiation of phase 3 study in 4q2016 .Plan to have phase 3 testing of mirvetuximab soravtansine up and running by year end.  Full Article

ImmunoGen Inc Updates FY 2016 guidance
Friday, 29 Apr 2016 06:30am EDT 

ImmunoGen Inc:Updated its guidance for FY 2016.Expected FY 2016 revenues are now projected to be between $60 million and $70 million, compared with previous guidance of between $70 million and $80 million.Guidance for FY 2016 net loss is now expected to be between $135 million and $140 million, compared to its previous estimate of $120 million and $125 million with most of this change being non-cash related.  Full Article

ImmunoGen Inc Appoints Mark J. Enyedy as President and Chief Executive Officer
Tuesday, 26 Apr 2016 08:00am EDT 

ImmunoGen Inc:Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16.Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.  Full Article

ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with keytruda
Thursday, 4 Feb 2016 08:00am EST 

ImmunoGen Inc:Says the company and Merck have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy.Says agreement is between immunogen and Merck, through a subsidiary.Says agreement includes a provision for potential expansion of the collaboration to include a subsequent phase 3 clinical trial.Additional details were not disclosed.  Full Article

BRIEF-Immunogen enters privately negotiated exchange agreements

* Immunogen-‍on Sept 25, co entered privately negotiated exchange agreements with some holders of co's outstanding 4.50% convertible senior notes due 2021​